AU2017248121B2 - T cell receptors - Google Patents

T cell receptors Download PDF

Info

Publication number: AU2017248121B2
Authority: AU; Australia
Prior art keywords: amino acid; sequence; tcr; seq; acid residues
Prior art date: 2016-04-08
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Ceased

Application number

AU2017248121A

Other languages

English (en)

Other versions

AU2017248121A1 (en

Inventor

Eleanor BAGG

William Lawrance

Nicholas TRIBBLE

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Adaptimmune Ltd

Original Assignee

Adaptimmune Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2016-04-08

Filing date

2017-04-10

Publication date

2022-07-21

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=58536983&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2017248121(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2017-04-10 Application filed by Adaptimmune Ltd filed Critical Adaptimmune Ltd

2018-11-22 Publication of AU2017248121A1 publication Critical patent/AU2017248121A1/en

2022-07-21 Application granted granted Critical

2022-07-21 Publication of AU2017248121B2 publication Critical patent/AU2017248121B2/en

2022-10-20 Priority to AU2022256182A priority Critical patent/AU2022256182A1/en

Status Ceased legal-status Critical Current

2037-04-10 Anticipated expiration legal-status Critical

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001111—Immunoglobulin superfamily
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
- A61K40/32—T-cell receptors [TCR]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4267—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
- A61K40/4268—MAGE
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Immunology (AREA)
Organic Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Engineering & Computer Science (AREA)
Zoology (AREA)
Epidemiology (AREA)
Medicinal Chemistry (AREA)
Genetics & Genomics (AREA)
Cell Biology (AREA)
Biomedical Technology (AREA)
Biochemistry (AREA)
Biotechnology (AREA)
Pharmacology & Pharmacy (AREA)
Bioinformatics & Cheminformatics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Wood Science & Technology (AREA)
Toxicology (AREA)
Biophysics (AREA)
Gastroenterology & Hepatology (AREA)
Molecular Biology (AREA)
Hematology (AREA)
Microbiology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
General Engineering & Computer Science (AREA)
Developmental Biology & Embryology (AREA)
Virology (AREA)
Oncology (AREA)
Mycology (AREA)
Peptides Or Proteins (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)

AU2017248121A 2016-04-08 2017-04-10 T cell receptors Ceased AU2017248121B2 (en)

Priority Applications (1)

Application Number	Priority Date	Filing Date	Title
AU2022256182A AU2022256182A1 (en)	2016-04-08	2022-10-20	T Cell Receptors

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
GB1606156.6		2016-04-08
GB201606156		2016-04-08
PCT/EP2017/058578 WO2017174823A1 (en)	2016-04-08	2017-04-10	T cell receptors

Related Child Applications (1)

Application Number	Title	Priority Date	Filing Date
AU2022256182A Division AU2022256182A1 (en)	2016-04-08	2022-10-20	T Cell Receptors

Publications (2)

Publication Number	Publication Date
AU2017248121A1 AU2017248121A1 (en)	2018-11-22
AU2017248121B2 true AU2017248121B2 (en)	2022-07-21

Family

ID=58536983

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
AU2017248121A Ceased AU2017248121B2 (en)	2016-04-08	2017-04-10	T cell receptors
AU2022256182A Abandoned AU2022256182A1 (en)	2016-04-08	2022-10-20	T Cell Receptors

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
AU2022256182A Abandoned AU2022256182A1 (en)	2016-04-08	2022-10-20	T Cell Receptors

Country Status (15)

Country	Link
US (3)	US20190144521A1 (ru)
EP (2)	EP3440104B2 (ru)
JP (2)	JP7204484B2 (ru)
KR (1)	KR20190065189A (ru)
CN (2)	CN109476724B (ru)
AU (2)	AU2017248121B2 (ru)
BR (1)	BR112018070637A2 (ru)
CA (1)	CA3020555A1 (ru)
ES (1)	ES2788188T5 (ru)
IL (1)	IL262124A (ru)
MX (1)	MX389173B (ru)
RU (1)	RU2018138837A (ru)
SG (1)	SG11201808750PA (ru)
WO (1)	WO2017174823A1 (ru)
ZA (1)	ZA201806862B (ru)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB201501017D0 (en)	2014-12-23	2015-03-04	Immatics Biotechnologies Gmbh	Novel peptides and combination of peptides for use in immunotherapy against hepatocellular carcinoma (HCC) and other cancers
HRP20211754T1 (hr)	2014-12-23	2022-03-04	Immatics Biotechnologies Gmbh	Novi peptidi i kombinacije peptida za upotrebu u imunoterapiji protiv hepatocelularnog karcinoma (hcc) i drugih rakova
EP4389898A3 (en)	2016-04-08	2024-09-04	Adaptimmune Ltd	T cell receptors
CN109476724B (zh)	2016-04-08	2023-04-04	艾达普特免疫有限公司	T细胞受体
SG11201808751SA (en)	2016-04-08	2018-11-29	Adaptimmune Ltd	T cell receptors
EP3692058A1 (en)	2017-10-06	2020-08-12	Oslo Universitetssykehus HF	Chimeric antigen receptors
US20210041435A1 (en) *	2018-01-31	2021-02-11	Tohoku University	Method for regulating antigen-specific mhc expression
EP3784255B1 (en) *	2018-04-19	2025-09-17	Board of Regents, The University of Texas System	T cell receptors with mage-b2 specificity and uses thereof
GB201819540D0 (en) *	2018-11-30	2019-01-16	Adaptimmune Ltd	T cell modification
CN110172091B (zh) *	2019-04-28	2020-04-03	天津亨佳生物科技发展有限公司	一种针对egfr l858r基因突变的特异性t细胞受体及其应用
WO2020257288A2 (en) *	2019-06-18	2020-12-24	Regeneron Pharmaceuticals, Inc.	Mage-a4 t cell receptors and methods of use thereof
PE20220231A1 (es)	2019-06-25	2022-02-07	Gilead Sciences Inc	Proteinas de fusion flt3l-fc y metodos de uso
US12480958B2 (en)	2019-08-13	2025-11-25	Immatics Biotechnologies Gmbh	Method for the characterization of peptide:MHC binding polypeptides
US20230000913A1 (en)	2019-08-13	2023-01-05	King's College London	Immunoresponsive cells armoured with spatiotemporally restricted activity of cytokines of the il-1 superfamily
BR112022014623A2 (pt)	2020-02-14	2022-09-13	Jounce Therapeutics Inc	Anticorpos e proteínas de fusão que se ligam a ccr8 e usos dos mesmos
JP2023527293A (ja)	2020-05-19	2023-06-28	アムジエン・インコーポレーテツド	Ｍａｇｅｂ２結合構築物
CN111647069B (zh) *	2020-06-17	2022-06-21	深圳豪石生物科技有限公司	一种改进的tcr及其应用
TWI815194B (zh)	2020-10-22	2023-09-11	美商基利科學股份有限公司	介白素2-Fc融合蛋白及使用方法
CA3205810A1 (en) *	2020-12-22	2022-06-30	Amgen Inc.	Mage-b2-specific t-cell receptors
EP4304725A1 (en)	2021-03-09	2024-01-17	CDR-Life AG	Rabbit-derived antigen binding protein nucleic acid libraries
JP2024509910A (ja)	2021-03-09	2024-03-05	シーディアール－ライフ・アクチェンゲゼルシャフト	Ｍａｇｅ－ａ４ペプチド－ｍｈｃ抗原結合タンパク質
US20220389394A1 (en)	2021-05-18	2022-12-08	Gilead Sciences, Inc.	METHODS OF USING FLT3L-Fc FUSION PROTEINS
AU2022375782A1 (en)	2021-10-28	2024-05-02	Gilead Sciences, Inc.	Pyridizin-3(2h)-one derivatives
PE20241186A1 (es)	2021-10-29	2024-06-03	Gilead Sciences Inc	Compuestos de cd73
EP4452414A2 (en)	2021-12-22	2024-10-30	Gilead Sciences, Inc.	Ikaros zinc finger family degraders and uses thereof
CA3237577A1 (en)	2021-12-22	2023-06-29	Gilead Sciences, Inc.	Ikaros zinc finger family degraders and uses thereof
TW202340168A (zh)	2022-01-28	2023-10-16	美商基利科學股份有限公司	Ｐａｒｐ７抑制劑
WO2023178181A1 (en)	2022-03-17	2023-09-21	Gilead Sciences, Inc.	Ikaros zinc finger family degraders and uses thereof
CN116836261A (zh) *	2022-03-24	2023-10-03	香雪生命科学技术（广东）有限公司	一种识别mage-a4抗原的高亲和力tcr及其序列和应用
WO2023205719A1 (en)	2022-04-21	2023-10-26	Gilead Sciences, Inc.	Kras g12d modulating compounds
CN117106060A (zh) *	2022-05-17	2023-11-24	香雪生命科学技术（广东）有限公司	一种识别mage的高亲和力t细胞受体及其应用
CA3260083A1 (en)	2022-07-01	2024-01-04	Gilead Sciences Inc	CD73 COMPOUNDS
KR20250067130A (ko)	2022-09-14	2025-05-14	씨디알-라이프 아게	Mage-a4 펩티드 이중 t 세포 연결체
US20240254118A1 (en)	2022-12-22	2024-08-01	Gilead Sciences, Inc.	Prmt5 inhibitors and uses thereof
AU2024252725A1 (en)	2023-04-11	2025-11-06	Gilead Sciences, Inc.	Kras modulating compounds
CN121079300A (zh)	2023-04-21	2025-12-05	吉利德科学公司	Prmt5抑制剂及其用途
WO2025006720A1 (en)	2023-06-30	2025-01-02	Gilead Sciences, Inc.	Kras modulating compounds
WO2025024811A1 (en)	2023-07-26	2025-01-30	Gilead Sciences, Inc.	Parp7 inhibitors
US20250066328A1 (en)	2023-07-26	2025-02-27	Gilead Sciences, Inc.	Parp7 inhibitors
TW202506719A (zh) *	2023-07-27	2025-02-16	德商艾瑪提克生物技術有限公司	針對mageb2之抗原結合蛋白
WO2025021979A1 (en) *	2023-07-27	2025-01-30	Immatics Biotechnologies Gmbh	Novel t cell receptors targeting melanoma-associated antigen (mage) b2 and immune therapy using the same
US20250109147A1 (en)	2023-09-08	2025-04-03	Gilead Sciences, Inc.	Kras g12d modulating compounds
WO2025054347A1 (en)	2023-09-08	2025-03-13	Gilead Sciences, Inc.	Kras g12d modulating compounds
WO2025096589A1 (en)	2023-11-03	2025-05-08	Gilead Sciences, Inc.	Prmt5 inhibitors and uses thereof
WO2025137640A1 (en)	2023-12-22	2025-06-26	Gilead Sciences, Inc.	Azaspiro wrn inhibitors
US20250376484A1 (en)	2024-05-21	2025-12-11	Gilead Sciences, Inc.	Prmt5 inhibitors and uses thereof

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6596536B1 (en) *	1991-02-08	2003-07-22	Aventis Pharma S.A.	Nucleotide sequences coding for variable regions of the alpha chains of human T lymphocyte receptors, corresponding peptide segments and the diagnostic and therapeutic uses
AU5992999A (en)	1998-10-02	2000-04-26	Ludwig Institute For Cancer Research	Tumor antigens and ctl clones isolated by a novel procedure
US6407063B1 (en) *	1998-10-02	2002-06-18	Ludwig Institute For Cancer Research	Tumor antigens and CTL clones isolated by a novel procedure
US6867283B2 (en)	2001-05-16	2005-03-15	Technion Research & Development Foundation Ltd.	Peptides capable of binding to MHC molecules, cells presenting such peptides, and pharmaceutical compositions comprising such peptides and/or cells
US20050053918A1 (en)	2001-05-16	2005-03-10	Technion Research & Development Foundation Ltd.	Method of identifying peptides capable of binding to MHC molecules, peptides identified thereby and their uses
JP4317940B2 (ja)	2001-08-31	2009-08-19	イミュノコア・リミテッド	物質
GB0304068D0 (en) *	2003-02-22	2003-03-26	Avidex Ltd	Substances
US20120009162A1 (en) *	2009-04-03	2012-01-12	Masaki Yasukawa	T cell receptor and nucleic acid encoding the receptor
JP2012529283A (ja)	2009-06-09	2012-11-22	ヴァクソンバイオテック	共有ｈｌａ−ｂ＊０７０２エピトープの同定、最適化および免疫療法のための使用
EP2618835B1 (en)	2010-09-20	2017-07-05	BioNTech Cell & Gene Therapies GmbH	Antigen-specific t cell receptors and t cell epitopes
JP2015502915A (ja) *	2011-10-14	2015-01-29	テバ・ファーマシューティカルズ・オーストラリア・ピーティワイ・リミテッド	ＣＤ１ｄに対する抗体
WO2014201021A2 (en) *	2013-06-10	2014-12-18	Dana-Farber Cancer Institute, Inc.	Methods and compositions for reducing immunosupression by tumor cells
JP6255360B2 (ja) *	2015-03-04	2017-12-27	ヴァクソンバイオテックＶａｘｏｎＢｉｏｔｅｃｈ	共有ｈｌａ−ｂ＊０７０２エピトープの同定、最適化および免疫療法のための使用
CN109476724B (zh) *	2016-04-08	2023-04-04	艾达普特免疫有限公司	T细胞受体
EP4389898A3 (en) *	2016-04-08	2024-09-04	Adaptimmune Ltd	T cell receptors
SG11201808751SA (en)	2016-04-08	2018-11-29	Adaptimmune Ltd	T cell receptors
DK3440105T3 (da) *	2016-04-08	2022-06-13	Immunocore Ltd	T-cellereceptorer

2017
- 2017-04-10 CN CN201780031701.3A patent/CN109476724B/zh active Active
- 2017-04-10 RU RU2018138837A patent/RU2018138837A/ru unknown
- 2017-04-10 CN CN202310214446.3A patent/CN116239669A/zh active Pending
- 2017-04-10 AU AU2017248121A patent/AU2017248121B2/en not_active Ceased
- 2017-04-10 EP EP17716871.3A patent/EP3440104B2/en active Active
- 2017-04-10 WO PCT/EP2017/058578 patent/WO2017174823A1/en not_active Ceased
- 2017-04-10 MX MX2018012268A patent/MX389173B/es unknown
- 2017-04-10 EP EP20020115.0A patent/EP3925972A1/en active Pending
- 2017-04-10 ES ES17716871T patent/ES2788188T5/es active Active
- 2017-04-10 SG SG11201808750PA patent/SG11201808750PA/en unknown
- 2017-04-10 BR BR112018070637A patent/BR112018070637A2/pt not_active Application Discontinuation
- 2017-04-10 CA CA3020555A patent/CA3020555A1/en active Pending
- 2017-04-10 KR KR1020187032157A patent/KR20190065189A/ko not_active Ceased
- 2017-04-10 JP JP2018552775A patent/JP7204484B2/ja active Active
2018
- 2018-10-04 IL IL262124A patent/IL262124A/en unknown
- 2018-10-08 US US16/154,270 patent/US20190144521A1/en not_active Abandoned
- 2018-10-15 ZA ZA2018/06862A patent/ZA201806862B/en unknown
2021
- 2021-10-14 US US17/501,200 patent/US11753456B2/en active Active
2022
- 2022-05-24 JP JP2022084419A patent/JP7572399B2/ja active Active
- 2022-10-20 AU AU2022256182A patent/AU2022256182A1/en not_active Abandoned
2023
- 2023-08-01 US US18/363,672 patent/US12180261B2/en active Active

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Duffour, et al., 1999. 'A MAGE-A4 peptide presented by HLA-A2 is recognized by cytolytic T lymphocytes'. Eur. J. Immunol. 29: 3329-3337 *

Also Published As

Publication number	Publication date
EP3440104B1 (en)	2020-03-11
IL262124A (en)	2018-11-29
EP3440104A1 (en)	2019-02-13
JP7204484B2 (ja)	2023-01-16
NZ747962A (en)	2024-12-20
MX389173B (es)	2025-03-20
AU2022256182A1 (en)	2022-11-24
RU2018138837A (ru)	2020-05-12
CA3020555A1 (en)	2017-10-12
CN109476724B (zh)	2023-04-04
BR112018070637A2 (pt)	2019-02-05
JP2022122913A (ja)	2022-08-23
SG11201808750PA (en)	2018-11-29
JP2019516356A (ja)	2019-06-20
EP3925972A1 (en)	2021-12-22
CN116239669A (zh)	2023-06-09
AU2017248121A1 (en)	2018-11-22
WO2017174823A1 (en)	2017-10-12
US11753456B2 (en)	2023-09-12
CN109476724A (zh)	2019-03-15
MX2018012268A (es)	2019-02-07
RU2018138837A3 (ru)	2020-07-30
ZA201806862B (en)	2021-04-28
WO2017174823A4 (en)	2017-12-07
US20220025013A1 (en)	2022-01-27
JP7572399B2 (ja)	2024-10-23
US20240010702A1 (en)	2024-01-11
US20190144521A1 (en)	2019-05-16
ES2788188T5 (es)	2023-10-24
EP3440104B2 (en)	2023-06-14
US12180261B2 (en)	2024-12-31
KR20190065189A (ko)	2019-06-11
ES2788188T3 (es)	2020-10-20

Publication	Publication Date	Title
AU2022256177B2 (en)	2025-03-20	T cell receptors
AU2022256181B2 (en)	2024-06-13	T Cell Receptors
US12180261B2 (en)	2024-12-31	T cell receptors
AU2014294830B2 (en)	2020-01-16	T cell receptors
AU2020203201A1 (en)	2020-06-04	T cell receptors
HK40066361A (en)	2022-08-19	T cell receptors
HK40073110A (en)	2022-12-09	T cell receptors
NZ787034A (en)	2022-04-29	T Cell Receptors

Legal Events

Date	Code	Title	Description
2022-11-17	FGA	Letters patent sealed or granted (standard patent)
2025-11-06	MK14	Patent ceased section 143(a) (annual fees not paid) or expired